Detalhe da pesquisa
1.
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.
Int J Mol Sci
; 23(10)2022 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35628286
2.
An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs.
Cancer Lett
; 554: 216024, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455759
3.
HER3 in cancer: from the bench to the bedside.
J Exp Clin Cancer Res
; 41(1): 310, 2022 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36271429
4.
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
Cancer Res
; 82(24): 4670-4679, 2022 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36222720
5.
Generation of Antibody-Drug Conjugate Resistant Models.
Cancers (Basel)
; 13(18)2021 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34572858
6.
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs.
Cancers (Basel)
; 14(1)2021 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35008318
7.
Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma.
J Exp Clin Cancer Res
; 40(1): 256, 2021 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34399807
8.
JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
Biomed Pharmacother
; 144: 112330, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34673425
9.
HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies.
EMBO Mol Med
; 12(5): e11498, 2020 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32329582
10.
Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
Cancer Lett
; 470: 161-169, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31765734